Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386782309> ?p ?o ?g. }
- W4386782309 abstract "Nail psoriasis is a common, physiologically, and psychologically disruptive, and yet often under-treated manifestation of psoriasis. The objectives of this analysis were to investigate the trajectory of nail psoriasis, a risk factor for psoriatic arthritis (PsA), with guselkumab vs adalimumab treatment followed by withdrawal, and determine characteristics associated with nail response in patients treated with guselkumab.This post hoc analysis of the phase III trial VOYAGE 2 included patients with moderate-to-severe plaque psoriasis and baseline nail involvement. Nail Psoriasis Severity Index (NAPSI) and Psoriasis Area and Severity Index (PASI) were analyzed through week 48 in patients randomized to guselkumab or adalimumab. Multiple logistic regression analyzed factors associated with NAPSI 0/1 at week 24/week 48 following guselkumab treatment. In a separate analysis, patients were stratified by prior biologic experience.Overall, 272 vs 132 patients receiving guselkumab vs adalimumab had nail psoriasis at baseline. Lower baseline NAPSI and week 16 PASI were associated with achieving NAPSI 0/1 at week 24 (NAPSI, odds ratio 0.685 [95% confidence interval: 0.586, 0.802]; week 16 PASI, 0.469 [0.281, 0.782]) and week 48 (NAPSI, 0.784 [0.674, 0.914]; week 16 PASI, 0.557 [0.331, 0.937]) with guselkumab. Previous biologic experience did not impact NAPSI response. Following treatment withdrawal at week 28, mean NAPSI was maintained in the guselkumab arm (week 24 1.7, week 48 1.9) and increased slightly in the adalimumab arm (week 24 1.4, week 48 2.3). Mean PASI increased across both treatment arms.Higher skin efficacy at week 16 was associated with better nail responses during guselkumab treatment. Nail psoriasis improvements reflected skin improvements. Following guselkumab withdrawal, nail response was maintained longer than skin response. Future studies should investigate whether such improvements in nail response reduce patients' risk of later PsA development.ClinicalTrials.gov, NCT02207244. Registered July 31, 2014." @default.
- W4386782309 created "2023-09-16" @default.
- W4386782309 creator A5009079207 @default.
- W4386782309 creator A5009244815 @default.
- W4386782309 creator A5018663852 @default.
- W4386782309 creator A5056126124 @default.
- W4386782309 creator A5070478316 @default.
- W4386782309 creator A5071307383 @default.
- W4386782309 creator A5074786702 @default.
- W4386782309 creator A5091798251 @default.
- W4386782309 date "2023-09-15" @default.
- W4386782309 modified "2023-10-09" @default.
- W4386782309 title "Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial" @default.
- W4386782309 cites W1147565511 @default.
- W4386782309 cites W1589811210 @default.
- W4386782309 cites W1968611206 @default.
- W4386782309 cites W2007386671 @default.
- W4386782309 cites W2011757107 @default.
- W4386782309 cites W2040737548 @default.
- W4386782309 cites W2056840860 @default.
- W4386782309 cites W2066002096 @default.
- W4386782309 cites W2067688080 @default.
- W4386782309 cites W2085199990 @default.
- W4386782309 cites W2103724612 @default.
- W4386782309 cites W2107839949 @default.
- W4386782309 cites W2124465016 @default.
- W4386782309 cites W2153652405 @default.
- W4386782309 cites W2155111110 @default.
- W4386782309 cites W2570140560 @default.
- W4386782309 cites W2570141807 @default.
- W4386782309 cites W2758035665 @default.
- W4386782309 cites W2804010661 @default.
- W4386782309 cites W2884544678 @default.
- W4386782309 cites W2900957628 @default.
- W4386782309 cites W2904527393 @default.
- W4386782309 cites W2920783701 @default.
- W4386782309 cites W2946605861 @default.
- W4386782309 cites W2965354284 @default.
- W4386782309 cites W3001269698 @default.
- W4386782309 cites W3027305906 @default.
- W4386782309 cites W3039953994 @default.
- W4386782309 cites W3131825027 @default.
- W4386782309 cites W3146784243 @default.
- W4386782309 cites W3190122872 @default.
- W4386782309 cites W3199301787 @default.
- W4386782309 cites W3200575265 @default.
- W4386782309 cites W3204237038 @default.
- W4386782309 cites W3207022229 @default.
- W4386782309 cites W3208273621 @default.
- W4386782309 cites W4210909636 @default.
- W4386782309 cites W4220973834 @default.
- W4386782309 cites W4283589104 @default.
- W4386782309 cites W4289594701 @default.
- W4386782309 cites W4307973407 @default.
- W4386782309 cites W4312181886 @default.
- W4386782309 doi "https://doi.org/10.1186/s13075-023-03138-z" @default.
- W4386782309 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37715294" @default.
- W4386782309 hasPublicationYear "2023" @default.
- W4386782309 type Work @default.
- W4386782309 citedByCount "0" @default.
- W4386782309 crossrefType "journal-article" @default.
- W4386782309 hasAuthorship W4386782309A5009079207 @default.
- W4386782309 hasAuthorship W4386782309A5009244815 @default.
- W4386782309 hasAuthorship W4386782309A5018663852 @default.
- W4386782309 hasAuthorship W4386782309A5056126124 @default.
- W4386782309 hasAuthorship W4386782309A5070478316 @default.
- W4386782309 hasAuthorship W4386782309A5071307383 @default.
- W4386782309 hasAuthorship W4386782309A5074786702 @default.
- W4386782309 hasAuthorship W4386782309A5091798251 @default.
- W4386782309 hasBestOaLocation W43867823091 @default.
- W4386782309 hasConcept C126322002 @default.
- W4386782309 hasConcept C16005928 @default.
- W4386782309 hasConcept C168563851 @default.
- W4386782309 hasConcept C2776260265 @default.
- W4386782309 hasConcept C2777011040 @default.
- W4386782309 hasConcept C2777575956 @default.
- W4386782309 hasConcept C2780132546 @default.
- W4386782309 hasConcept C2780564577 @default.
- W4386782309 hasConcept C3020604521 @default.
- W4386782309 hasConcept C67761136 @default.
- W4386782309 hasConcept C71924100 @default.
- W4386782309 hasConceptScore W4386782309C126322002 @default.
- W4386782309 hasConceptScore W4386782309C16005928 @default.
- W4386782309 hasConceptScore W4386782309C168563851 @default.
- W4386782309 hasConceptScore W4386782309C2776260265 @default.
- W4386782309 hasConceptScore W4386782309C2777011040 @default.
- W4386782309 hasConceptScore W4386782309C2777575956 @default.
- W4386782309 hasConceptScore W4386782309C2780132546 @default.
- W4386782309 hasConceptScore W4386782309C2780564577 @default.
- W4386782309 hasConceptScore W4386782309C3020604521 @default.
- W4386782309 hasConceptScore W4386782309C67761136 @default.
- W4386782309 hasConceptScore W4386782309C71924100 @default.
- W4386782309 hasIssue "1" @default.
- W4386782309 hasLocation W43867823091 @default.
- W4386782309 hasLocation W43867823092 @default.
- W4386782309 hasOpenAccess W4386782309 @default.
- W4386782309 hasPrimaryLocation W43867823091 @default.
- W4386782309 hasRelatedWork W107859310 @default.
- W4386782309 hasRelatedWork W1589811210 @default.
- W4386782309 hasRelatedWork W1975941816 @default.